Posts by Patrick T. Ellinor, MD, PhD
-
AI Finds Associations Between Genetically Predicted LV Mass and Future CV Events
Massachusetts General Hospital researchers used artificial intelligence (AI) to conduct a genome-wide association study of indexed left ventricular mass (LVMI) derived from cardiac MRI, identifying 11 novel associations and linking both actual and genetically predicted LVMI to higher risk of multiple CV conditions.
-
New Model Uses Ordinary Clinical Data to Estimate Ascending Aortic Diameter in Asymptomatic Individuals
Patrick T. Ellinor, MD, PhD, James P. Pirruccello, MD, and colleagues have developed an online calculator based on common demographic and clinical characteristics that estimates thoracic aortic diameter in asymptomatic patients, and thus may predict aortic dissection and rupture.
-
Polygenic Risk Score Identifies Individuals at Risk of Thoracic Aortic Aneurysm
James P. Pirruccello, MD, Patrick T. Ellinor, MD, PhD, Mark Lindsay, MD, PhD, and colleagues used artificial intelligence to reveal the genetic basis of aortic size variation, then built a polygenic risk score that predicted future risk of thoracic aortic aneurysm. Their findings may also point to new therapeutic targets.
-
ADAMTS7 Knockdown Might Treat Atherosclerosis
Patrick T. Ellinor, MD, PhD, of the Telemachus & Irene Demoulas Family Foundation Center for Cardiac Arrhythmias at Massachusetts General Hospital, Sekar Kathiresan, MD, formerly of the Center for Genomic Medicine, and colleagues have demonstrated that the catalytic domain of ADAMTS7 is a promising therapeutic target for coronary artery disease.
-
Non–Vitamin K Antagonist Oral Anticoagulants Are Safe for Selected Patients with Postoperative AF
Patrick T. Ellinor, MD, PhD, Steven A. Lubitz, MD, MPH, Thor M. Sundt, MD, and colleagues determined that after cardiac surgery, non–vitamin K antagonist oral anticoagulants are a safe alternative to warfarin for patients with nonvalvular atrial fibrillation who have acceptable bleeding risk.
-
Researchers Develop Detailed Cellular Map of the Heart
A study led by a Massachusetts General Hospital cardiologist used single nucleus sequencing to create a novel, detailed cellular map of the heart.
-
Pathologic Link Detected Between COVID-19 and Myocarditis
Levels of ACE2, the receptor for SARS-CoV-2, are increased in cardiomyocytes but are not affected by ACE inhibitors.
-
Leveraging Social Media in Medicine
A group from the Massachusetts General Hospital Corrigan Minehan Heart Center discusses how they leverage social media as both practicing clinicians and active researchers.
-
Novel Genetic Signals for Heart Failure Identified
Researchers at Massachusetts General have found evidence of distinct genetic signals for heart failure—including some that operate independently of traditional risk factors for heart failure and associate with subclinical disease.
-
Frequency of Cardiac Rhythm Abnormalities in a Half Million Adults
Researchers at Massachusetts General Hospital recently published the results of their analysis of arrhythmias in the UK Biobank, a national cohort of over 500k community-based individuals recruited to assess risk factors for disorders affecting people from middle-age onward.
-
Using Polygenic Scores to Identify Risk of Afib and 4 Other Common Diseases
Polygenic risk scores developed at Massachusetts General Hospital are equivalent to or better than rare monogenic mutations in identifying a specific individual’s risk of certain common diseases, including coronary artery disease, atrial fibrillation and type 2 diabetes.
-
Lifetime Risk for Atrial Fibrillation Higher Than Expected
Lifetime risk for atrial fibrillation, while high, can be modified with health changes
-
Largest genetic study establishes hereditary links to atrial fibrillation
A study led by Mass General cardiologist Patrick T. Ellinor, MD, PhD, identified 97 genetic loci that are significantly associated with atrial fibrillation.
-
The Role of Genomics in Atrial Fibrillation
Patrick Ellinor, MD, PhD, director of the Telemachus & Irene Demoulas Family Foundation Center for Cardiac Arrhythmias at Massachusetts General Hospital, discusses his team’s recent work leveraging genome-wide association studies to identify over 100 different genetic determinants of atrial fibrillation, and his hope of using those variants to develop new drugs to treat atrial fibrillation in the years to come.
-
#AHA17 Video: Scientific Sessions in Summary
Mass General physicians presented on the podium, moderated sessions or showcased posters over 50 times at the American Heart Association 2017 Scientific Sessions. Some of them answered the question: “What was the most interesting topic presented at this year’s Scientific Sessions?"
Biography
Dr. Ellinor was raised in Cincinnati and graduated summa cum laude from the University of Cincinnati with a degree in Biology. He attended Stanford University for medical and graduate school. After completing doctoral work in the laboratory of Dr. Richard Tsien, he moved to Boston for medical residency at Brigham and Women’s Hospital. He then completed cardiology and cardiac electrophysiology fellowship training at Massachusetts General Hospital. Dr. Ellinor joined the staff of Mass General in 2001, served as the Medical Director of the Cardiac Step-Down Unit for thirteen years, and recently became the Director of the Telemachus & Irene Demoulas Family Foundation Center for Cardiac Arrhythmias. He is a Professor of Medicine at Harvard Medical School and an Associate Member at the Broad Institute.
Dr. Ellinor’s research work has focused on identifying the molecular basis of atrial fibrillation. His research laboratories are located in the Cardiovascular Research Center at Mass General and at the Broad Institute of Harvard and MIT. Dr. Ellinor currently helps to lead the AFGen Consortium, an international group of investigators studying the genetics of atrial fibrillation. Over the past 15 years, he has been continuously funded by the NIH, he has received an Established Investigator Award from the AHA, and he is a principal investigator on a Transatlantic Research Network sponsored by the Fondation Leducq. Dr. Ellinor is a member of the American Heart Association, the Heart Rhythm Society and the American Society of Clinical Investigation.